Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
66.00    -0.50 (-0.75%)
Bid:
65.00
Ask:
67.00
Spread: 2.00 (3.077%)
Market Cap: £16.08m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Trading Update

20 Jan 2026 07:00

RNS Number : 4533P
MyCelx Technologies Corporation
20 January 2026
 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

20 January 2026

 

MYCELX Technologies Corporation

("MYCELX" or the "Company")

 

MYCELX Achieves Profitability in 2025 Outperforming Market Expectations

 

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, is pleased to provide a year-end financial update, reporting expected profitability that significantly exceeds market expectations, along with an update on the Company's strategy for its core markets.

 

The Company expects FY2025 year-end revenue of c.a. $11.7 million, a 140% improvement over FY2024, although slightly less than market expectations of $12.5 million.

 

While EBITDA and profit before tax ('PBT') remain subject to year-end closing procedures, the Company expects EBITDA to be in the region of $680,000, a 131% improvement over FY2024, which includes a gain of $160,000 from the sale of its Saudi Arabia operations, and $520,000 without the gain, compared to market expectations of an EBITDA loss of $200,000.

 

PBT is expected to be in the region of $360,000, including the gain. This materially exceeds the market expectations of a PBT loss of $600,000. Excluding this gain, PBT is c.a. $200,000.

 

This outperformance reflects strict cost discipline, operating leverage, and an increased contribution from higher-margin revenue.

 

Cash and cash equivalents at year-end are $860,000, including $50,000 restricted cash. The Company also expects to collect approximately $4 million in cash during Q1 2026.

 

Current Trading and Outlook

 

We enter 2026 with a stronger earnings profile, a streamlined organization, and increasing commercial momentum across our core markets in the U.S. and internationally. The actions taken in 2024 and executed in 2025 have repositioned the Company for faster customer adoption, multiple project wins, and improved cash generation. Our relationships in the Middle East remain strong, and traction in the U.S. is accelerating following successful trials and deployments with both existing and new customers. We remain disciplined in capital allocation and margin expansion as we scale the business and focus on delivering sustainable, long-term value.

 

While the Company is optimistic about the prospects for 2026 and beyond, at this point in the year the company is maintaining current year guidance and will update the market in due course when there is greater visibility on a number of major contracts.

 

Strategic Update

 

The Company's core markets have been refined to concentrate on Produced Water, PFAS and Water Services (industrial water treatment) as the key focus markets. Produced Water treatment remains the primary focus. PFAS Remediation is slowly evolving into a major market, and the Company is engaged in specific verticals within PFAS that currently have budget to spend. In the case of Water Services, the Company has been selling legacy products into niche applications that add high margin revenue and growing that incremental business will be achieved by expanding roles and repositioning current personnel.

 

The Board was pleased to elevate Matthew Goysich, Director of Engineering, to Executive Vice President and Jim Weidler, to Executive Vice President of Business Development. Both executives have joined the Executive Management team and will attend Board Meetings to provide their insight on our core markets and commercial and strategic plan progress. We congratulate both Matthew and Jim on their well-earned promotions.

 

The Company will make new hires this year in Engineering and Business Development in Q1. The engineering hire will allow Matthew to spend more time with key clients, closing sales and influencing tactics and strategy. Driving our business in the Permian Basin requires an experienced sales professional with relationships and water experience. This initiative and overall sales and marketing reporting and activity will be managed by Jim Weidler.

 

Connie Mixon, CEO, commented:

 

"Achieving profitability represents an important inflection point for MYCELX. Our reputation for delivering advanced technology that economically provides better performance is increasingly recognized among key market players globally. We are excited to continue to vigorously execute our successful strategy to win more business and strengthen our financial profile as we create long-term value for all stakeholders".

 

 

For further information, please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

Giles Balleny / Callum Davidson / Elysia Bough (Corporate Finance)

Harriet Ward (Corporate Broking)

Jasper Berry / Michael Johnson (Sales)

 

 

 

Tel: +44 20 7220 0500

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKCBBDBKDKDD
Date   Source Headline
27th Jul 20187:00 amRNSContract Extension in Saudi Arabia
11th Jul 20181:16 pmRNSResult of Annual Meeting
7th Jun 20184:23 pmRNSBlock listing Interim Review
7th Jun 20183:42 pmRNSAnnual Financial Report
15th May 20187:00 amRNSFinal Results for the year ending 31 December 2017
19th Apr 20187:00 amRNSNew Purchase Order Award and Equipment Sale
13th Apr 201810:18 amRNSIssue of Equity
10th Apr 20187:00 amRNSPurchase Order Award & General Manager Appointment
28th Mar 201812:48 pmRNSHolding(s) in Company
16th Feb 20187:00 amRNSIssue of Equity
6th Feb 20187:00 amRNSExtension of Contract and New Project
17th Jan 20187:00 amRNSTrading Update
7th Dec 20179:46 amRNSBlock listing Interim Review
3rd Nov 201712:39 pmRNSIssue of Equity
26th Oct 20177:30 amRNSHolding(s) in Company
9th Oct 20177:00 amRNSIssue of Equity
27th Sep 20172:44 pmRNSApplication for Block Admission
26th Sep 20175:31 pmRNSClosure of Restricted Stock Line
21st Sep 20177:00 amRNSConsolidation of Stock Lines
13th Sep 20177:00 amRNSHalf Year Results Statement
12th Jul 201712:30 pmRNSResult of Annual Meeting
7th Jul 20177:00 amRNSHalf Year Trading Update
9th Jun 201710:00 amRNSMailing of Annual Financial Report & GM Notice
7th Jun 201710:30 amRNSBlock listing Interim Review
30th May 20171:19 pmRNSDirector/PDMR Shareholding
26th May 20177:00 amRNSContract win with new SABIC affiliate customer
11th May 20177:00 amRNSFinal Results for the year ending 31 December 2016
8th May 20177:00 amRNSContract Award & Notification of Full Year Results
30th Jan 20177:00 amRNSTrading Update
7th Dec 20162:34 pmRNSBlock listing Interim Review
4th Oct 20167:00 amRNSAppointment of Nominated Adviser & Broker
14th Sep 20167:00 amRNSHalf Year Results Statement
13th Jul 20164:21 pmRNSResult of AGM
11th Jul 20167:00 amRNSHalf Year Trading Update
30th Jun 20167:00 amRNSHolding(s) in Company
24th Jun 20167:00 amRNSMyCelx and Schlumberger Sign Upstream Agreement
9th Jun 20167:00 amRNSMailing of 2015 Annual Report and Notice of AGM
7th Jun 20163:32 pmRNSBlock listing Interim Review
17th May 20167:00 amRNSFinal Results
16th Mar 20167:00 amRNSAppointment of CFO/Grant of Share Options
4th Mar 20161:25 pmRNSHolding(s) in Company
4th Mar 20167:00 amRNSTrading Update
11th Jan 20165:30 pmRNSHolding(s) in Company
29th Dec 20152:23 pmRNSHolding(s) in Company
18th Dec 201510:13 amRNSHolding(s) in Company
15th Dec 20155:25 pmRNSHolding(s) in Company
15th Dec 20155:24 pmRNSHolding(s) in Company
11th Dec 20157:00 amRNSTrading Update
3rd Dec 201511:33 amRNSBlocklisting Interim Review
1st Oct 20157:00 amRNSProgress Update on Trials

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.